Canaan Partners is a global venture capital firm that invests in entrepreneurs with visionary ideas. With $4.2 billion under management and over 180 exits to date, Canaan has funded some of the world's leading technology companies including LendingClub, Ebates, PrimeSense, and Skybox Imaging as well as healthcare stars like Chimerix, Durata, Labrys Biologics, and Civitas Therapeutics. Canaan recently announced Fund X, a $675 million fund focused on early stage IT and healthcare startups. The fund's healthcare focus includes early stage biopharma, medical devices, and digital health.
Wende Hutton, General Partner, will be in attendance on January 26th to provide an overview presentation of Canaan's areas of interest and best practices when applying for funding. Wende will be on hand to meet with a handful of applicants 1-on-1 after the presentation.
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ended on December 1st, 2015.
Canaan Partners Participating Representative:
Wende Hutton | General Partner, Canaan Partners
Healthcare investor Wende Hutton brings 20 years of experience to identifying, investing in and building companies that are changing the practice of medicine. She has facilitated bringing over a dozen medical devices and drugs to market, and currently sits on the boards of Butterfly Health, Chrono Therapeutics, Dermira, Glooko, ReVision Optics, Theraclone Sciences and Transcend Medical. Prior investments include BiPar Sciences (acquired by Sanofi-aventis), Chimerix (CMRX), and Labrys Biologics (acquired by Teva Pharmaceutical). Wende was recognized among Fierce Biotech's 2014 "Fierce 15" women in biotech and honored as one of The Most Influential Women in Bay Area Business 2015 by The San Francisco Business Times. Wende joined Canaan in 2004, and her life sciences track record includes seven IPOs and five acquisitions. She began her venture career at Mayfield Fund in 1993, where she worked closely with the founding teams of Heartstream (HPQ) and Northstar Neuroscience (NSTR). Earlier in her career, Wende held senior operational management positions at GenPharm International and Nellcor in business development and marketing. Wende holds an AB in human biology from Stanford University and an MBA from Harvard Business School, where she was a Baker Scholar. She is active with several community service groups including serving on the board of FACE AIDS.
Connect with Wende:
Out of the Digital Health Fog, More Investments Are Coming in 2015 - Xconomy
Influential Women 2015 List - San Francisco Business Times
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until January 25th, 2016 (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on December 1st, 2015. Your application will be reviewed and you will be notified of acceptance by January 5th, 2016 . Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Johnson & Johnson Innovation, JLABS
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
When & Where
JLABS Bay Area
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.